Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like N*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000106 Neos Therapeutics, Inc. 12/31/2019 70165002030 Amphetamine Tab Extended Release Disintegrating 12.5 MG, 30 Each, Unit-Dose, Box 10/02/2019 21.04 360.00 06/28/2032 Single Source Drug 57947 None The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations. None No significant change/improvement has been made to the drug. None None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2019 70165002530 Amphetamine Tab Extended Release Disintegrating 15.7 MG, 30 Each, Unit-Dose, Box 10/02/2019 21.04 360.00 06/28/2032 Single Source Drug 41574 None The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations. None No significant change/improvement has been made to the drug. None None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2019 70165003030 Amphetamine Tab Extended Release Disintegrating 18.8 MG, 30 Each, Unit-Dose, Box 10/02/2019 21.04 360.00 06/28/2032 Single Source Drug 54773 None The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations. None No significant change/improvement has been made to the drug. None None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2019 70165000530 Amphetamine Tab Extended Release Disintegrating 3.1 MG, 30 Each, Unit-Dose, Box 10/02/2019 21.04 360.00 06/28/2032 Single Source Drug 16182 None The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations. None No significant change/improvement has been made to the drug. None None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2019 70165001030 Amphetamine Tab Extended Release Disintegrating 6.3 MG, 30 Each, Unit-Dose, Box 10/02/2019 21.04 360.00 06/28/2032 Single Source Drug 43882 None The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations. None No significant change/improvement has been made to the drug. None None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2019 70165001530 Amphetamine Tab Extended Release Disintegrating 9.4 MG, 30 Each, Unit-Dose, Box 10/02/2019 21.04 360.00 06/28/2032 Single Source Drug 47478 None The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations. None No significant change/improvement has been made to the drug. None None None None None None None None None None None None
Rx0000420 Nielsen BioSciences, Inc. 06/30/2019 59584013801 Candin Skin Test Antigen liquid 1U/0.1mL 1.0mL 04/01/2019 16.00 208.00 None Single Source Drug 30808 None When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None None None None None None None None None None None None None None
Rx0000420 Nielsen BioSciences, Inc. 06/30/2019 59584014001 Spherusol Skin Test Antigen liquid 1.27mg/0.1mL 1.0mL 05/01/2019 58.00 787.00 None Single Source Drug 3672 None When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None None None None None None None None None None None None None None
Rx0000226 Nostrum Laboratories, Inc. 06/30/2019 70408018534 Promethazine-Codeine Oral Solution 6.25-10mg/5ml 473ml 04/29/2019 130.55 170.55 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was acquired on December 15th, 2015
Rx0000073 Novartis 03/31/2019 00078056751 Afinitor 10mg 01/15/2019 1163.46 15706.71 07/01/2028 Single Source Drug 40705 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078059451 Afinitor 2.5mg 01/15/2019 1112.31 15016.22 07/01/2028 Single Source Drug 4919 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078056651 Afinitor 5mg 01/15/2019 1163.46 15706.71 07/01/2028 Single Source Drug 24034 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078062051 Afinitor 7.5mg 01/15/2019 1163.46 15706.71 07/01/2028 Single Source Drug 9617 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078062651 Afinitor Disperz 2mg 01/15/2019 1106.77 14941.34 03/27/2023 Single Source Drug 2264 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078062751 Afinitor Disperz 3mg 01/15/2019 1117.85 15091.01 03/27/2023 Single Source Drug 1317 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078062851 Afinitor Disperz 5mg 01/15/2019 1163.46 15706.71 03/27/2023 Single Source Drug 2274 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00065027510 Azopt 1% 10mL 01/15/2019 22.84 308.38 04/24/2013 Single Source Drug 862600 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065027515 Azopt 1% 15mL 01/15/2019 34.26 462.52 04/24/2013 Single Source Drug 125099 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065853110 CIPRO®*HC Otic 0.2% / 1% 01/15/2019 17.88 315.87 06/06/2015 Single Source Drug 101653 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065853302 CIPRODEX 0.3% / 0.1% 01/15/2019 17.49 236.10 06/04/2025 Single Source Drug 2456190 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078063968 Cosentyx 150mg/ml (Sensoready Pen x1) 01/15/2019 466.53 5178.91 05/05/2033 Single Source Drug 100219 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078063941 Cosentyx 150mg/ml (Sensoready Pen x2) 01/15/2019 466.53 5178.91 05/05/2033 Single Source Drug 445341 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078063997 Cosentyx 150mg/ml (Syringe x1) 01/15/2019 466.53 5178.91 05/05/2033 Single Source Drug 24196 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078063998 Cosentyx 150mg/ml (Syringe x2) 01/15/2019 466.53 5178.91 05/05/2033 Single Source Drug 62077 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078035934 Diovan 160mg 01/15/2019 43.02 760.10 12/18/2017 Innovator Multiple Source Drug 53106 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078036034 Diovan 320mg 01/15/2019 54.43 961.59 12/18/2017 Innovator Multiple Source Drug 28511 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078042315 Diovan 40mg 01/15/2019 11.16 197.11 12/18/2017 Innovator Multiple Source Drug 33507 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078035834 Diovan 80mg 01/15/2019 40.01 706.86 12/18/2017 Innovator Multiple Source Drug 39159 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078031534 Diovan HCT 160/12.5mg 01/15/2019 48.96 864.89 12/18/2017 Innovator Multiple Source Drug 14702 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078038334 Diovan HCT 160/25mg 01/15/2019 55.52 980.84 12/18/2017 Innovator Multiple Source Drug 7625 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078047134 Diovan HCT 320/12.5mg 01/15/2019 62.03 1095.79 12/18/2017 Innovator Multiple Source Drug 4168 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078047234 Diovan HCT 320/25mg 01/15/2019 70.37 1243.17 12/18/2017 Innovator Multiple Source Drug 8923 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078031434 Diovan HCT 80/12.5mg 01/15/2019 45.00 794.92 12/18/2017 Innovator Multiple Source Drug 8335 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00065924007 Durezol 0.05% 5mL 01/15/2019 13.82 186.54 11/18/2019 Single Source Drug 1132752 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078065967 Entresto 24/26mg - 180 Each Bottle 01/15/2019 137.59 1527.36 05/27/2027 Single Source Drug 23309 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078065920 Entresto 24/26mg - 60 Each Bottle 01/15/2019 45.86 509.12 05/27/2027 Single Source Drug 917623 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078077767 Entresto 49/51mg - 180 Each Bottle 01/15/2019 137.59 1527.36 05/27/2027 Single Source Drug 26020 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078077720 Entresto 49/51mg - 60 Each Bottle 01/15/2019 45.86 509.12 05/27/2027 Single Source Drug 599199 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078069667 Entresto 97/103mg - 180 Each Bottle 01/15/2019 137.59 1527.36 05/27/2027 Single Source Drug 23469 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078069620 Entresto 97/103mg - 60 Each Bottle 01/15/2019 45.86 509.12 05/27/2027 Single Source Drug 408813 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078050315 Exelon Patch 13.3mg 01/15/2019 38.83 686.00 01/08/2019 Innovator Multiple Source Drug 39581 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078050115 Exelon Patch 4.6mg 01/15/2019 38.83 686.00 01/08/2019 Innovator Multiple Source Drug 62102 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078050215 Exelon Patch 9.5mg 01/15/2019 38.83 686.00 01/08/2019 Innovator Multiple Source Drug 86757 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078048915 Exforge 10/160 mg 01/15/2019 17.07 301.64 07/08/2019 Innovator Multiple Source Drug 5961 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078049115 Exforge 10/320 mg 01/15/2019 21.68 382.93 07/08/2019 Innovator Multiple Source Drug 12067 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078048815 Exforge 5/160 mg 01/15/2019 15.05 265.91 07/08/2019 Innovator Multiple Source Drug 35502 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078049015 Exforge 5/320 mg 01/15/2019 19.09 337.28 07/08/2019 Innovator Multiple Source Drug 8485 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078056215 Exforge HCT 10/160 mg/25 mg 01/15/2019 17.07 301.64 11/16/2023 Innovator Multiple Source Drug 6282 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=429, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=434 All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073 Novartis 03/31/2019 00078056115 Exforge HCT 10/160/12.5 mg 01/15/2019 17.07 301.64 11/16/2023 Innovator Multiple Source Drug 1352 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=428, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=433 All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073 Novartis 03/31/2019 00078056315 Exforge HCT 10/320 mg/25 mg 01/15/2019 21.68 382.93 11/16/2023 Innovator Multiple Source Drug 6123 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=430, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=435 All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073 Novartis 03/31/2019 00078055915 Exforge HCT 5/160/12.5mg 01/15/2019 15.05 265.91 11/16/2023 Innovator Multiple Source Drug 3466 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=426, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=431 All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073 Novartis 03/31/2019 00078056015 Exforge HCT 5/160/25 mg 01/15/2019 15.05 265.91 11/16/2023 Innovator Multiple Source Drug 6019 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=427, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=432 All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073 Novartis 03/31/2019 00078046815 Exjade 125mg 01/15/2019 93.84 1266.85 04/05/2019 Single Source Drug 4693 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078046915 Exjade 250mg 01/15/2019 187.68 2533.65 04/05/2019 Single Source Drug 9125 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078047015 Exjade 500mg 01/15/2019 375.35 5067.20 04/05/2019 Single Source Drug 27583 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078056912 Extavia .3 mg/vial 01/15/2019 378.25 6682.37 11/07/2021 Single Source Drug 13075 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078043105 Focalin XR 10mg 01/15/2019 72.86 1287.20 11/01/2019 Innovator Multiple Source Drug 77663 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078049305 Focalin XR 15mg 01/15/2019 74.93 1323.73 11/01/2019 Innovator Multiple Source Drug 66143 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078043205 Focalin XR 20mg 01/15/2019 74.93 1323.73 11/01/2019 Innovator Multiple Source Drug 70040 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078060805 Focalin XR 25mg 01/15/2019 78.68 1389.95 11/01/2019 Innovator Multiple Source Drug 29849 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078043305 Focalin XR 30mg 01/15/2019 72.18 1275.17 11/01/2019 Innovator Multiple Source Drug 36603 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078060905 Focalin XR 35mg 01/15/2019 82.61 1459.50 11/01/2019 Innovator Multiple Source Drug 7406 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078043405 Focalin XR 40mg 01/15/2019 82.61 1459.50 11/01/2019 Innovator Multiple Source Drug 17314 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078043005 Focalin XR 5mg 01/15/2019 71.80 1268.42 11/01/2019 Innovator Multiple Source Drug 34946 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078060715 Gilenya Capsule 0.5mg 01/15/2019 353.57 8210.64 12/27/2027 Single Source Drug 339976 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00065175007 Ilevro 0.3% 1.7mL 01/15/2019 20.38 275.08 03/31/2032 Single Source Drug 305539 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065175014 Ilevro 0.3% 3mL 01/15/2019 20.38 275.08 03/31/2032 Single Source Drug 213723 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078065515 Jadenu 180mg 01/15/2019 187.68 2533.65 11/21/2034 Single Source Drug 30116 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078065615 Jadenu 360mg 01/15/2019 375.35 5067.20 11/21/2034 Single Source Drug 98334 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078065415 Jadenu 90mg 01/15/2019 93.84 1266.85 11/21/2034 Single Source Drug 14792 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078071315 Jadenu Granules 180mg 01/15/2019 187.68 2533.65 04/05/2019 Single Source Drug 1772 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078072015 Jadenu Granules 360mg 01/15/2019 375.35 5067.20 04/05/2019 Single Source Drug 3271 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078072715 Jadenu Granules 90mg 01/15/2019 93.84 1266.85 04/05/2019 Single Source Drug 2316 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078036405 Lotrel 10/20mg 01/15/2019 65.93 1164.73 12/19/2017 Innovator Multiple Source Drug 4681 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078037905 Lotrel 10/40mg 01/15/2019 72.64 1283.36 12/19/2017 Innovator Multiple Source Drug 3729 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078040505 Lotrel 5/10mg 01/15/2019 53.74 949.33 12/19/2017 Innovator Multiple Source Drug 2961 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078040605 Lotrel 5/20mg 01/15/2019 56.75 1002.51 12/19/2017 Innovator Multiple Source Drug 5829 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078066615 Mekinist 0.5 mg 01/15/2019 158.40 3326.33 01/28/2032 Single Source Drug 16900 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00065000203 Nevanac 01/15/2019 15.38 271.63 01/31/2027 Single Source Drug 80133 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065027225 Pataday 01/15/2019 10.56 186.64 05/12/2024 Innovator Multiple Source Drug 123218 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065027105 Patanol 01/15/2019 16.45 290.61 12/06/2015 Innovator Multiple Source Drug 38786 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065427325 Pazeo 0.007 2.5mL 01/15/2019 14.42 194.71 05/19/2032 Single Source Drug 1160772 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078068415 Promacta 12.5 mg 01/15/2019 364.92 4926.47 02/01/2028 Single Source Drug 6735 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00078068515 Promacta 25 mg 01/15/2019 364.92 4926.47 02/01/2028 Single Source Drug 32813 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00078068615 Promacta 50 mg 01/15/2019 660.40 8915.34 02/01/2028 Single Source Drug 42737 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00078068715 Promacta 75 mg 01/15/2019 990.59 13373.01 02/01/2028 Single Source Drug 19289 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00078081181 Sandostatin LAR Depot 10mg (Diluent Filled Syringe) 01/15/2019 140.17 3255.10 01/30/2017 Single Source Drug 8369 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078081881 Sandostatin LAR Depot 20mg (Diluent Filled Syringe) 01/15/2019 183.65 4264.74 01/30/2017 Single Source Drug 114384 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078082581 Sandostatin LAR Depot 30mg (Diluent Filled Syringe) 01/15/2019 275.00 6386.14 01/30/2017 Single Source Drug 143662 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00065414727 Simbrinza 1% / 0.2% 8mL 01/15/2019 12.05 162.73 01/30/2017 Single Source Drug 870297 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078068266 Tafinlar 50 mg 01/15/2019 385.29 8091.04 10/15/2030 Single Source Drug 4581 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00078059287 Tasigna 150mg 01/15/2019 1018.76 13753.29 10/07/2032 Single Source Drug 55098 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078052687 Tasigna 200mg 01/15/2019 1018.76 13753.29 10/07/2032 Single Source Drug 22313 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078095166 Tasigna 50mg 01/15/2019 1091.53 14735.62 10/07/2032 Single Source Drug 191 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078050883 Tegretol 100mg/5ml 01/15/2019 9.24 163.20 10/11/2000 Innovator Multiple Source Drug 34854 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078050905 Tegretol 200mg 01/15/2019 14.34 253.38 10/11/2000 Innovator Multiple Source Drug 163517 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078051005 Tegretol-XR 100mg 01/15/2019 7.68 135.63 02/08/2011 Innovator Multiple Source Drug 63308 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078051105 Tegretol-XR 200mg 01/15/2019 15.32 270.70 02/08/2011 Innovator Multiple Source Drug 103462 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078051205 Tegretol-XR 400mg 01/15/2019 30.62 540.98 02/08/2011 Innovator Multiple Source Drug 54265 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00065064835 Tobradex ointment 0.3% / 0.1% 3.5g 01/15/2019 12.92 228.21 09/22/2009 Single Source Drug 428077 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065026025 Travatan Z 0.00004 2.5mL 01/15/2019 13.62 183.87 10/13/2029 Single Source Drug 2415488 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00065026005 Travatan Z 0.00004 5mL 01/15/2019 27.24 367.72 10/13/2029 Single Source Drug 604258 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078045605 Trileptal 150mg 01/15/2019 27.05 477.84 08/12/2018 Innovator Multiple Source Drug 9756 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078033705 Trileptal 300mg 01/15/2019 49.40 872.71 08/12/2018 Innovator Multiple Source Drug 37237 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078045705 Trileptal 600mg 01/15/2019 90.79 1603.97 08/12/2018 Innovator Multiple Source Drug 22874 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078035752 Trileptal-Oral Susp 250ml 01/15/2019 22.75 401.99 06/19/2021 Innovator Multiple Source Drug 69063 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078067119 Tykerb 250 mg 01/15/2019 448.18 7917.83 09/18/2029 Single Source Drug 13643 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 03/31/2019 00065401303 Vigamox 01/15/2019 9.86 174.12 03/29/2020 Innovator Multiple Source Drug 370430 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2019 00078067066 Votrient 200 mg 01/15/2019 968.78 13078.52 12/19/2021 Single Source Drug 42635 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073 Novartis 12/31/2019 54092060601 Xiidra 50mg/mL 12/03/2019 31.33 553.54 07/25/2033 Single Source Drug 218077 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None 06/30/2019 Takada/Shire 5300000000 None None 522.21 507.00 2016 426.73 None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2019 00078064070 Zykadia 150mg 01/15/2019 464.62 8208.31 02/02/2032 Single Source Drug 3452 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968051408 Estradiol & Norethindrone Acetate 0.05-0.14 MG/DAY Patch Twice Weekly 8 EA UU 01/01/2019 17.26 191.61 None Single Source Drug None 1 None 1 None 1 08/13/2014 Novartis None 1 Not a matter of public record 80.50 None 1998 23.75 https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=34 No existing patents WAC at Intro to market for Combipatch, which was launched in 1998, is not available to us. The first listing of WAC price we could find in PriceRx was as follows: Combipatch 0.05 mg-0.14 mg - 68968051408 (which was originally Sanofi Aventis-labeled as 00075051408) had a WAC of $23.75 on 9/17/98. We acquired this product on 8/13/2014. The WAC upon acquisition was $80.50. One full year before we acquired this product, the WAC was $70.06
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968052508 Estradiol & Norethindrone Acetate 0.05-0.25 MG/DAY Patch Twice Weekly 8 EA UU 01/01/2019 17.26 191.61 None Single Source Drug None 1 None 1 None 1 08/13/2014 Novartis None 1 Not a matter of public record. 80.40 None 1998 23.75 https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=35 No existing patents WAC at Intro to market for Combipatch, which was launched in 1998, is not available to us. The first listing of WAC price we could find in PriceRx was as follows: Combipatch 0.05 mg-0.25 mg - 68968052508 (which was oringianally Sanofi Aventis-labeled as 00075052508) had a WAC of $23.75 on 11/23/98. We acquired this product on 8/13/2014. The WAC upon acquisition was $80.40. One full year before we acquired this product, the WAC was $69.97.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555203 Methylphenidate 10 MG/9HR Patch 30 EA UU 01/01/2019 28.98 362.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555203 Methylphenidate 10 MG/9HR Patch 30 EA UU 01/15/2019 4.00 366.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=36 Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555303 Methylphenidate 15 MG/9HR Patch 30 EA UU 01/01/2019 28.98 362.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555303 Methylphenidate 15 MG/9HR Patch 30 EA UU 01/15/2019 4.00 366.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=37 Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555403 Methylphenidate 20 MG/9HR Patch 30 EA UU 01/01/2019 28.98 362.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555403 Methylphenidate 20 MG/9HR Patch 30 EA UU 01/15/2019 4.00 366.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=38 Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555503 Methylphenidate 30 MG/9HR Patch 30 EA UU 01/01/2019 28.98 362.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017 Noven Therapeutics, LLC 03/31/2019 68968555503 Methylphenidate 30 MG/9HR Patch 30 EA UU 01/15/2019 4.00 366.12 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=39 Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000033 Novo 03/31/2019 00169406012 Victoza? 6mg/mL 2x3mL 01/08/2019 34.26 614.52 08/22/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #6268343 which is the compound patent for Victoza. NNI has applied for pediatric exclusivity. If granted, this will add 6 months to all Orange Book exclusivities. NNI is the original manufacturer of this product (Victoza) and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2019 00169406013 Victoza? 6mg/mL 3x3mL 01/08/2019 51.39 921.78 08/22/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #6268343 which is the compound patent for Victoza. NNI has applied for pediatric exclusivity. If granted, this will add 6 months to all Orange Book exclusivities. NNI is the original manufacturer of this product (Victoza) and did not acquire the product from a different company.